Hydralazine Morningside Healthcare (Hydralazine Hydrochloride)

Hydralazine Morningside Healthcare is indicated for the treatment of hypertension, particularly in patients who require additional blood pressure control beyond first‑line agents.

• As monotherapy in mild to moderate essential hypertension when other agents are insufficient.
• In combination with beta‑blockers, diuretics, or ACE inhibitors to achieve target blood pressure.
• For hypertensive emergencies where rapid vasodilation is desired, under close medical supervision.
• To manage hypertension in patients with renal impairment where other vasodilators may be contraindicated.
• Occasionally used off‑label for heart failure with reduced ejection fraction, following specialist guidance.

• Hydralazine acts directly on arteriolar smooth muscle by interfering with intracellular calcium metabolism and inhibiting the release of endothelin, leading to vasodilation. The drug relaxes vascular smooth muscle independent of sympathetic or renin‑angiotensin pathways, thereby decreasing peripheral vascular resistance and lowering arterial pressure. Its effect is rapid, with onset within minutes, and it does not significantly affect venous tone.

Like all antihypertensive agents, hydralazine may cause adverse reactions that vary in frequency and severity.

Common

• Headache
• Flushing or sensation of warmth
• Reflex tachycardia
• Nausea or vomiting
• Peripheral edema

Serious

• Lupus‑like syndrome (cutaneous or systemic)
• Severe hypotension
• Acute renal impairment
• Myocardial ischemia (rare)

Healthcare professionals should evaluate patient history and monitor clinical parameters before and during hydralazine therapy.

• Assess baseline blood pressure and heart rate to detect excessive hypotension.
• Monitor for signs of drug‑induced lupus, especially in patients with a history of autoimmune disease.
• Use caution in patients with coronary artery disease, as reflex tachycardia may increase myocardial oxygen demand.
• Evaluate renal and hepatic function periodically, adjusting therapy as needed.
• Avoid abrupt discontinuation to prevent rebound hypertension.
• Consider dose adjustments in pregnant or lactating women only when benefits outweigh risks.

Hydralazine can interact with several medications, altering its efficacy or increasing the risk of adverse effects.

Avoid

• Concurrent use with other direct vasodilators (e.g., nitroglycerin) may cause profound hypotension.
• Combining with beta‑blockers without careful monitoring can mask reflex tachycardia.
• Co‑administration with MAO inhibitors may increase hypertensive crises risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce antihypertensive effect.
• ACE inhibitors or ARBs may enhance hypotensive response.
• Diuretics may increase the likelihood of reflex tachycardia.
• Oral contraceptives may diminish blood pressure control.